A Phase I/II Study of DYP688 for People with Advanced Uveal Melanoma and Other Melanomas with GNAQ/11 Gene Mutations


Full Title

A Phase I/II, Multi-Center, Open Label Study of DYP688 in Patients with Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas


The purpose of this study is to find the highest dose of the investigational drug DYP688 that can be given safely in people with metastatic uveal melanoma, mucosal melanoma, or skin melanoma that contains mutations in the GNAQ or GNA11 genes. These mutated genes make proteins called GPCR that cause melanoma cells to grow and spread.

DYP688 attaches to a protein on the surface of melanoma cells and brings an anticancer drug inside the cells to block the action of GPCR, causing the cancer cells to die. It is given intravenously (by vein).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have metastatic uveal melanoma of any genetic type, or another type of melanoma that harbors a mutation in the GNAQ or GNA11 genes.
  • The serious side effects of prior treatments must go away before the study treatment is given.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Alexander Shoushtari at 646-888-4161.




Phase I/II (phases 1 and 2 combined)

Disease Status

Newly Diagnosed & Relapsed/Refractory


ClinicalTrials.gov ID